uniQure N.V.

What they do

uniQure develops single-treatment gene therapies for rare and devastating diseases, with clinical candidates in Huntington's disease (AMT-130), refractory mesial temporal lobe epilepsy (AMT-260), and Fabry disease. AMT-130 uses the company's miQURE gene-silencing platform with a miRNA designed to silence the huntingtin gene and the exon 1 protein fragment. The company is conducting Phase I/II trials of AMT-130 in the U.S. and Europe and a Phase I/IIa study of AMT-260.

Revenue drivers

• AMT-130 (Huntington's disease) — Lead candidate and the company's primary near-term value driver; no product revenue is generated today, with a BLA submission planned for the third quarter of 2026.
• AMT-260 (refractory MTLE) — Earlier-stage Phase I/IIa gene therapy candidate; in June 2026 the company reported preliminary six-month data from the first low-dose cohort of six patients.
• Fabry disease program — Listed among the company's clinical pipeline candidates; no financial contribution or trial results were disclosed in the excerpts provided.
• Financing activities — The company funds operations through equity and debt financings rather than product sales, including a June 2026 follow-on offering and a Hercules term loan facility.

Recent performance

In July 2026, uniQure reported second-quarter 2026 financial results and said it remains on track to submit a U.S. and U.K. regulatory submission for AMT-130 in the third quarter of 2026. In June 2026, the company received net proceeds of $242.7 million from a follow-on offering of 5.7 million ordinary shares at $45.50 per share, and the earnings release described a $259 million follow-on offering extending cash runway into 2030. In June 2026, the company announced preliminary six-month data from the first low-dose cohort of AMT-260 in refractory MTLE: three of six patients had disabling-seizure reductions of 79% to 100% from baseline during months four through six, while the other three ranged from a 33% decrease to a 36% increase. No SAEs related to AMT-260 or the surgical procedure were reported as of the June 19, 2026 presentation date.

Strategy

The company's stated priority is to submit a BLA for AMT-130 in the third quarter of 2026 under the accelerated approval pathway, following a June 2026 Type B FDA meeting whose July 2026 minutes confirmed alignment that a BLA based on existing clinical data is reasonable. The FDA also seeks alignment on a confirmatory study design prior to submission, including consideration of a randomized standard-of-care control instead of a sham procedure. Management plans to initiate the confirmatory study as expeditiously as possible after aligning with the FDA, and to continue pipeline investment, including AMT-260 and the Fabry program. The company strengthened its balance sheet with a follow-on offering that it says extends cash runway into 2030 and funds the anticipated commercial launch of AMT-130.

Risks

• Dependence on AMT-130 — The company states it has invested a significant portion of its development efforts and financial resources in AMT-130, so failure in clinical development, regulatory approval, manufacturing, or commercialization could materially harm the business.
• Regulatory and confirmatory study uncertainty — The FDA wants alignment on a confirmatory study design before the BLA submission, including a possible randomized standard-of-care control rather than a sham procedure, and the 10-K risk factors reference a December 2025 announcement about a final meeting.
• Need for additional capital — The company has no product revenue and depends on financings, with the 10-K citing its need for additional financing and the period for which existing cash resources will be sufficient.
• Early-stage pipeline data — AMT-260 low-dose cohort results were mixed, with three of six patients showing variable changes in disabling seizures ranging from a 33% decrease to a 36% increase, so clinical benefit is not yet established.

Outlook

Management expects to submit a BLA for AMT-130 in the third quarter of 2026 and to present four-year follow-up data in September 2026 on all patients in the first two cohorts, including 24 patients with four years of follow-up. U.K. regulatory submission activities with the MHRA are also progressing as planned for the third quarter of 2026. The company says its strengthened financial position extends cash runway into 2030 and funds the anticipated commercial launch of AMT-130 and continued pipeline investment.